Abstract: There is disclosed a monophosphorylated cyclic lipopeptide compound obtained by biophosphorylating a cyclic lipopeptide related to echinocandins and having a peptide skeleton bearing several hydroxy groups wherein in the phosphorylated cyclic lipopeptide, the phosphate group is attached to the hydroxy group of the 4-hydroxyproline component of the lipopeptide. The compounds are useful for the control of fungi and parasites.
Type:
Grant
Filed:
April 26, 1991
Date of Patent:
March 30, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Shieh-Shung T. Chen, David J. Mathre, Brian R. Petuch, Robert A. Reamer
Abstract: A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N G y V l G n V l G u T r I e S r P o G y A p G y A g T r P e P o L s A g-Gly-Gln-Thr-X-Val-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Fly-Lys-Phe-AS p (wherein X is undefined). The HCBV protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g. Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyses the cis-trans isomerization of proline-containing peptide bonds.
Type:
Grant
Filed:
June 27, 1991
Date of Patent:
March 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
John J. Siekierka, Hsuen-Yun Hung, Marie J. Staruch, Nolan H. Sigal, Richard A. Mumford
Abstract: 17.beta.-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5.alpha.-reductase inhibitors of the formula: ##STR1## wherein R is C.sub.3 -C.sub.8 cycloalkyl, which can be substituted with C.sub.1 -C.sub.4 alkoxy or C.sub.6 -C.sub.12 aryl, which can be substituted with one or more of: --OH, --OC.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkyl, --(CH.sub.2).sub.m OH, --(CH.sub.2).sub.n COOH, including protected --OH, where m is 1-4, n is 1-3, and pharmaceutically acceptable salts or esters thereof. Also described is a pharmaceutical formulation. The above compounds are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of acne, seborrhea, female hirsutism, and systemically in treatment of benign prostatic hypertrophy.
Type:
Grant
Filed:
August 16, 1991
Date of Patent:
March 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Gary H. Rasmusson, Richard L. Tolman, Gool F. Patel
Abstract: A fermented malt beverage having improved foam stability and desirable lace, cling, and clarity is described. The beverage is stabilized by adding 5-400 ppm by weight of combined gellan gum and a cold-water soluble protein.
Type:
Grant
Filed:
May 23, 1990
Date of Patent:
March 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Kenneth Clare, deceased, Margaret A. Lawson
Abstract: A class of substituted cyclic sulphamide derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
Abstract: Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
Type:
Grant
Filed:
October 7, 1991
Date of Patent:
March 16, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Gino M. Salituro, Francis Dumont, George M. Garrity, Leeyuan Huang, E. Tracy T. Jones, Mary N. Omstead, Isabel M. Fernandez, Teresa D. Matas
Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Type:
Grant
Filed:
February 27, 1992
Date of Patent:
March 9, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
Abstract: A method for the modification of treatment of an immuno regulatory disorder or disease with an FK-506-type immunosuppressive macrolide comprising the administration to a mammalian species in need of such modification of an effective amount of a compound of the formula I.
Type:
Grant
Filed:
September 26, 1991
Date of Patent:
March 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Thomas R. Beattie, Matthew J. Wyvratt, Francis J. Dumont
Abstract: There are disclosed a method and an assemblage for controlling and managing lower explosion levels of those products containing volatile or combustible materials which can create a potentially explosive or combustible atmosphere when such products are dried or subjected to further processing in an oven or furnace.
Abstract: A fermented malt beverage having improved foam stability and desirable lace, cling, and clarity is described. The beverage is stabilized by adding 5-400 ppm by weight of gellan gum.
Type:
Grant
Filed:
May 23, 1990
Date of Patent:
March 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Kenneth Clare, deceased, Margaret A. Lawson
Abstract: A protein having a molecular weight of about 6,000 daltons which is biologically active in the inhibition of Factor Xa during the blood coagulation cascade, a method for producing the protein, methods for inhibiting blood coagulation using the protein, and suitable pharmaceutical compositions.
Type:
Grant
Filed:
April 23, 1990
Date of Patent:
February 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Linda O. Palladino, Melvin Silberklang, Jwu-Sheng Tung, Simon W. Law, George E. Mark
Abstract: Fluoromacrolides and derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by oxidation and fluorination at C-20. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses. Also, these macrolides are useful in the treatment of reversible obstructive airways disease, particularly asthma. Furthermore, these macrolides are useful as hair revitalizing agents, especially in the treatment of male pattern alopecia or alopecia senilis.
Type:
Grant
Filed:
August 22, 1991
Date of Patent:
February 23, 1993
Assignee:
Merck & Co. Inc.
Inventors:
Mark Goulet, Thomas R. Beattie, Matthew J. Wyvratt
Abstract: Novel dipeptide isosteres are the biotransformed products after incubation with rat liver slices. They inhibit HIV protease, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Type:
Grant
Filed:
February 27, 1992
Date of Patent:
February 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Suresh K. Balani, Harri G. Ramjit, Steven M. Pitzenberger, Michael S. Schwartz, Anthony Y. H. Lu
Abstract: A novel single-pot trialkylsilyl trifluoromethanesulfonate (R.sub.3 Si-OTf) mediated process produces derivatives of 4-aza 3-keto steroids at the .alpha.-methylenic carbon through electrophilic substitution. These derivatives are useful in the preparation, through elimination of the substituent on the .alpha.-methylene carbon, of .DELTA.-1 olefin 4-aza 3-keto steroids which are potent inhibitors of 5-.alpha. reductase.
Type:
Grant
Filed:
November 1, 1991
Date of Patent:
February 16, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Anthony O. King, Kevin Anderson, Sandor Karady, Alan W. Douglas, Newton L. Abramson, Richard F. Shuman
Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Type:
Grant
Filed:
February 20, 1992
Date of Patent:
February 16, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
Abstract: Fermentation of the microorganism Actinoplanacete sp. (MA6559), ATTC No. 53771, in the presence of the HIV reverse transcriptase inhibitor ##STR1## yields 3-[2-(benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2(1H)-pyridinone and 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-hydroxymethyl-2(1H)-pyridinone, both of which are useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
Abstract: Described are new agents for treating bone disorders associated with a reduction in bone mass and abnormalities in bone resportion or bone formation including osteoporosis. Paget's disease, bone metastases and malignant hypercalcemia. The agents are hydroxyl containing steroidal hormones, having bone resportion antagonist or bone formation stimulatory activity, covalently linked through the hydroxyl group via a bond hydrolyzable in the human body, e.g. carbamate or carbonate, which is further covalently linked to an amino, or hydroxy substituted alkylidene-1,1-bisphosphonate, through the respective amino or hydroxy group. The alkyl bisphosphonate moiety confers bone affinity. The agent acts by delivering the steroidal hormone directly to the bone target site where it is released for bone resorption antagonist or bone formation stimulatory action by hydrolysis of the hydrolyzable covalent bond.
Type:
Grant
Filed:
February 19, 1992
Date of Patent:
February 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Walfred S. Saari, Gideon A. Rodan, Thorsten E. Fisher, Paul S. Anderson
Abstract: An antiviral agent produced by Hypoxylon fragiforme and having the structure: ##STR1## is described. The product has high activity as an HIV protease enzyme inhibitor and is useful in the treatment of diseases in which control of HIV protease activity is desirable.
Type:
Grant
Filed:
September 25, 1990
Date of Patent:
February 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Gerald F. Bills, Otto D. Hensens, Lawrence Koupal, Russell B. Lingham, John G. Ondeyka, Deborah L. Zink
Abstract: Monofluorophosphate salts, especially sodium monofluorophosphate (Na.sub.2 PO.sub.3 F), when added to various industrial water systems in concentrations between 0.1 mg/L and 50 mg/L, significantly reduce the amount of calcium carbonate scale which is formed on heat exchange and other metallic surfaces of such systems.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 0.1 mg/L and 50 mg/L also stabilizes soluble manganese ion and its reaction products, i.e., primarily MnO.sub.2, in desirable forms and reduced particle sizes.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 1 mg/L and 500 mg/L also stabilizes soluble iron ion and its reaction products, i.e., primarily Fe.sub.2 O.sub.3.